Adicet Bio (ACET) Consolidated Net Income (2017 - 2026)

Adicet Bio's Consolidated Net Income history runs 10 years deep, the most recent figure standing at -$20.2 million for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 28.25% year-over-year to -$20.2 million; the TTM figure through Mar 2026 stood at -$47.1 million (down 254.8% YoY), while the FY2025 annual figure was $86000.0, up 437.5% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$20.2 million, down from $46000.0 in the prior quarter.
• The five-year high for Consolidated Net Income was $88.4 million in Q4 2024, with the low at -$49.9 million in Q3 2023.
• The 5-year median for Consolidated Net Income is -$22.5 million (2022), against an average of -$13.3 million.
• Peak annual rise in Consolidated Net Income reached 121.66% in 2022, while the deepest fall reached 199863.64% in 2022.
• Adicet Bio's Consolidated Net Income stood at -$29.9 million in 2022, then sank by 66.98% to -$49.9 million in 2023, then soared by 277.23% to $88.4 million in 2024, then sank by 99.95% to $46000.0 in 2025, then sank by 44108.7% to -$20.2 million in 2026.
• Business Quant data shows ACET's Consolidated Net Income at -$20.2 million in Q1 2026, $46000.0 in Q4 2025, and -$26.9 million in Q3 2025.